Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials.
Goyal A, Schibler T, Alhanti B, Hannan KL, Granger CB, Blazing MA, Lopes RD, Alexander JH, Peterson ED, Rao SV, Green JB, Roe MT, Rorick T, Berdan LG, Reist C, Mahaffey KW, Harrington RA, Califf RM, Patel MR, Hernandez AF, Jones WS. Goyal A, et al. Among authors: blazing ma. JAMA Netw Open. 2021 Jul 1;4(7):e2117963. doi: 10.1001/jamanetworkopen.2021.17963. JAMA Netw Open. 2021. PMID: 34297072 Free PMC article.
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA, de Lemos JA, White HD, Fox KA, Verheugt FW, Ardissino D, DiBattiste PM, Palmisano J, Bilheimer DW, Snapinn SM, Ramsey KE, Gardner LH, Hasselblad V, Pfeffer MA, Lewis EF, Braunwald E, Califf RM; 'A to Z' Investigators. Blazing MA, et al. JAMA. 2004 Jul 7;292(1):55-64. doi: 10.1001/jama.292.1.55. JAMA. 2004. PMID: 15238591 Clinical Trial.
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf RM. Petersen JL, et al. Among authors: blazing ma. JAMA. 2004 Jul 7;292(1):89-96. doi: 10.1001/jama.292.1.89. JAMA. 2004. PMID: 15238596 Review.
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial.
de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E; Investigators. de Lemos JA, et al. Among authors: blazing ma. JAMA. 2004 Sep 15;292(11):1307-16. doi: 10.1001/jama.292.11.1307. Epub 2004 Aug 30. JAMA. 2004. PMID: 15337732 Clinical Trial.
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Murphy SA, Cannon CP, Wiviott SD, de Lemos JA, Blazing MA, McCabe CH, Califf RM, Braunwald E. Murphy SA, et al. Among authors: blazing ma. Am J Cardiol. 2007 Oct 1;100(7):1047-51. doi: 10.1016/j.amjcard.2007.04.053. Epub 2007 Jul 18. Am J Cardiol. 2007. PMID: 17884359 Clinical Trial.
105 results